J M Goldman
Overview
Explore the profile of J M Goldman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
700
Citations
7576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taj A, Martiat P, Dhut S, Chaplin T, Dowding C, Thng K, et al.
Leuk Lymphoma
. 2016 Jul;
3(3):201-8.
PMID: 27457438
We designed experiments to study the effects on P210BCR/ABL expression of introducing antisense oligonucleotides into K562 cells. We used two antisense oligonucleotides: one (AS1) is complementary to the first coding...
2.
Goldman J
Leuk Lymphoma
. 2016 Jul;
3(3):159-64.
PMID: 27457433
The management of the newly diagnosed patient with CML has become more complex in recent years. For the younger patient (aged <50 years) with an HLA-identical sibling allogeneic bone marrow...
3.
Goldman J, Gordon M, Bazeos A, Marin D
Leuk Suppl
. 2016 May;
1(Suppl 2):S43-5.
PMID: 27175247
Although chronic myeloid leukemia (CML) is now defined on the basis of the presence of the BCR-ABL1 fusion gene, which may or may not be the initial genetic event that...
4.
Gonon-Demoulian R, Goldman J, Nicolini F
Bull Cancer
. 2014 Feb;
101(1):56-67.
PMID: 24491668
During two centuries, advances in medicine and medical research have helped to understand the pathophysiology of chronic myelogenous leukemia (CML). This hematologic malignancy is a unique model of oncogenesis where...
5.
Cortes J, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al.
N Engl J Med
. 2013 Nov;
369(19):1783-96.
PMID: 24180494
Background: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a...
6.
7.
Khoury H, Kukreja M, Goldman J, Wang T, Halter J, Arora M, et al.
Bone Marrow Transplant
. 2011 Oct;
47(6):810-6.
PMID: 21986636
Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit...
8.
Marin D, Gabriel I, Ahmad S, Foroni L, de Lavallade H, Clark R, et al.
Leukemia
. 2011 Aug;
26(2):296-302.
PMID: 21844874
Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer immunoglobulin-like receptors (KIR) may influence...
9.
Bazeos A, Marin D, Reid A, Gerrard G, Milojkovic D, May P, et al.
Leukemia
. 2010 May;
24(6):1243-5.
PMID: 20445576
No abstract available.
10.
van Rood J, Goldman J
Bone Marrow Transplant
. 2010 Feb;
45(5):843-5.
PMID: 20173791
No abstract available.